Skip to main content

Beximco Pharmaceuticals Limited (BXP.L)

London Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
69.8Fair

ValueMarkers Composite Index

Top 99%#455 of 44,722
Undervalued

73% below intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
9/9
Strong
Beneish
-2.08
Investigate
Altman
1.96
Grey Zone
DCF Value
$1
Undervalued
ROIC
10.6%
Adequate
P/E
5.4
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Beximco Pharmaceuticals Limited (BXP.L) — VMCI valuation read

Beximco Pharmaceuticals Limited (BXP.L) carries a VMCI composite of 70/100, 20 points above the Healthcare sector median of 50. Among mid-cap names, that gap places BXP.L in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The BXP.L insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads BXP.L trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -0.8x leaves covenant headroom, the line to track on Beximco Pharmaceuticals Limited's next 10-Q.

BXP.L rose 0.4% over the trailing 7 days, with a -14.1% read on a 30-day basis.

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

CEO: Iqbal U. Ahmed6,000 employeesBDwww.beximcopharma.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.